NKcell alloreactivity in acute myeloid leukemia in the post-transplant cyclophosphamide era

Catharina H. M. J. Van Elssen, Stefan O. Ciurea*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

3 Citations (Web of Science)

Abstract

Allogeneic hematopoietic stem cell transplantation (alloSCT) for myeloid leukemia remains one of the most effective anti-tumor treatments available, capable of curing an increasingly higher proportion of patients. Alloreactivity generated by T cells has limited efficacy in the early post-transplant period while most patients will relapse within 6 months after transplantation. Prior studies in T cell depleted grafts showed that, with the elimination of T cells, natural killer (NK) cells provide most of the anti-tumor effect in the early post-transplant period. Administration of unmodified T cells to mitigate infections and relapse will expose the patient to a high risk of graft-vs-host disease (GvHD). Post-transplant cyclophosphamide (PTCy), initially used for haploidentical (haplo) donor transplants, is now also increasingly utilized in HLA matched donor transplants to prevent GvHD. In most patients, PTCy eliminates, at least in part, alloreactive T and NK cells early post-transplant. Administration of modified NK cells in the early post-transplant period makes intuitive sense to enhance the anti-tumor effect of the graft and thereby prevent relapse. Effective application of cellular therapy early after transplant has opened a new direction and could revolutionize the field of hematopoietic stem cell transplantation.

Original languageEnglish
Pages (from-to)1590-1598
Number of pages9
JournalAmerican Journal of Hematology
Volume95
Issue number12
DOIs
Publication statusPublished - Dec 2020

Keywords

  • STEM-CELL TRANSPLANTATION
  • NATURAL-KILLER-CELLS
  • BONE-MARROW-TRANSPLANTATION
  • MINIMAL RESIDUAL DISEASE
  • VERSUS-HOST-DISEASE
  • KIR LIGAND INCOMPATIBILITY
  • ANTI-THYMOCYTE GLOBULIN
  • PROSPECTIVE PHASE-II
  • RISK ACUTE-LEUKEMIA
  • HEMATOLOGIC MALIGNANCIES

Cite this